Has Bernard Taylor, MD received payments from drug or device companies?

Yes. Drug and device makers reported $28,312 in general payments to Bernard Taylor, MD across 106 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bernard Taylor, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bernard Taylor, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bernard Taylor, MD

Radiation Oncology · Longview, TXNPI 1205878345

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $17,347 of the $28,312 with a category attached, or 61.3%. Isoray, Inc accounts for 74.3% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2020 at $13,527 and has fallen 95.4% since, to $622 in 2025. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$28,312in general payments, 2019–2025

Across 106 payments — averaging $267.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Isoray, Inc$21K
Bayer$6K
Bioprotect Medical, Inc.$219
Varian Medical Systems, Inc.$193
Johnson & Johnson$143
Theragenics Corporation$137
plus $1K from 22 others

$24,119in research payments, 2019–2025

Across 2 payments — averaging $12,060 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novocure Inc.$24K

What the payments were for

Consulting fees$17,34761%
Speaking & faculty fees$5,90021%
Food & beverage$4,96918%
Education$970%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Isoray, Inc	35	$21,045
Bayer	13	$5,526
Bioprotect Medical, Inc.	2	$219
Varian Medical Systems, Inc.	2	$193
Johnson & Johnson(2 entities)	5	$143
Theragenics Corporation	1	$137
Novocure Inc.	7	$117
Bard Peripheral Vascular, Inc.	1	$113
Pfizer	4	$101
Novartis	5	$92
Regeneron Healthcare Solutions, Inc.	4	$89
Elekta, Inc.	4	$71
AbbVie	2	$65
AstraZeneca	3	$47
Blue Earth Diagnostics	2	$43
Jazz Pharmaceuticals Inc.	2	$43
Visionrt, Inc.	1	$39
Incyte Corporation	2	$39
AVEO Pharmaceuticals, Inc.	2	$36
Teleflex LLC	1	$33
Boston Scientific	1	$21
Merck	1	$20
Sirtex Medical Inc	1	$15
Caris MPI, Inc.	1	$15
EMD Serono, Inc.	1	$15
Lilly USA, LLC	1	$14
Epizyme, Inc.	1	$12
Analogic Corporation	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Brachytherapy Source$20,316
Xofigo$5,254
BIOPROTECT BALLOON IMPLANT SYSTEM$120
TrueBeam$120
Model 200 TheraSeed Palladium-103 in ReadyLink$113
Nubeqa$109

How this compares

$28,312 in reported general payments places this provider in the 90th percentile of 418 radiation oncology providers in Texas.

See all radiation oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$1,660,569

Medicare patients

406

Services billed

10,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	173	$1,772
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	25	$1,473
Triamcinolone Acetonide	41	$747
SsdSilver Sulfadiazine	21	$632
Methylprednisolone	28	$243
Ciprofloxacin Hcl	17	$126

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Longview

James WelshHouston$421K
Stephen ChunHouston$344K
Jim HsiangCorpus Christi$258K
Chad TangHouston$183K
Phuoc TranHouston$177K
Hak ChoyDallas$119K
Steven LinHouston$105K
Benjamin SchrankHouston$100K
Robert TimmermanDallas$77K
Abhilasha PatelHouston$76K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →